Clinical Trial Update: A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) [Phase 3]

View source ↗

Summary

Phase 3 study evaluating efruxifermin in adults with noninvasively diagnosed nonalcoholic steatohepatitis and nonalcoholic fatty liver disease; the trial is cur…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonalcoholic Fatty Liver Disease
• Nonalcoholic Steatohepatitis

Drugs mentioned

• efruxifermin (efruxifermin)

Snippet

Sponsor: Akero Therapeutics, Inc | Conditions: NASH/MASH, NAFLD/MASLD | Phase 3 | Status: ACTIVE_NOT_RECRUITING